Foghorn Therapeutics' low P/S ratio may be due to investor s...
Foghorn Therapeutics' low P/S ratio may be due to investor skepticism about sustained strong revenue. The company's forecasted growth, lower than the industry average, could be causing shareholder unease and potentially impeding a strong share price rise.
Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Shares Bounce 28% But Its Business Still Trails The Industry
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment